Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Assets (2016 - 2025)

Agios Pharmaceuticals' Non-Current Assets history spans 14 years, with the latest figure at $355.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 49.09% year-over-year to $355.2 million; the TTM value through Dec 2025 reached $1.7 billion, changed 0.24%, while the annual FY2025 figure was $355.2 million, 49.09% down from the prior year.
  • Non-Current Assets reached $355.2 million in Q4 2025 per AGIO's latest filing, up from $352.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $717.6 million in Q3 2024 to a low of $103.3 million in Q4 2023.
  • Average Non-Current Assets over 5 years is $352.1 million, with a median of $357.4 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: crashed 74.56% in 2023, then skyrocketed 575.42% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $373.5 million in 2021, then grew by 8.69% to $405.9 million in 2022, then crashed by 74.56% to $103.3 million in 2023, then surged by 575.42% to $697.6 million in 2024, then plummeted by 49.09% to $355.2 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Non-Current Assets are $355.2 million (Q4 2025), $352.6 million (Q3 2025), and $451.8 million (Q2 2025).